伟思医疗(688580) - 2023 Q1 - 季度财报

Financial Performance - In Q1 2023, the total revenue reached CNY 95,539,491.61, representing a year-on-year increase of 76.57%[5] - The net profit attributable to shareholders was CNY 30,081,694.57, up 76.85% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 26,468,101.27, showing a significant increase of 190.81% year-on-year[5] - Basic earnings per share were CNY 0.4406, reflecting a growth of 77.02%[6] - The total revenue for Q1 2023 was CNY 95,539,491.61, representing a 76.6% increase compared to CNY 54,107,297.63 in Q1 2022[19] - The net profit for Q1 2023 was CNY 30,081,694.57, which is a 76.9% increase from CNY 17,009,682.26 in Q1 2022[20] - The basic earnings per share for Q1 2023 was CNY 0.4406, compared to CNY 0.2489 in Q1 2022, reflecting a 77.0% increase[21] Expenses and Costs - Research and development expenses totaled CNY 15,218,176.47, which accounted for 15.93% of total revenue, a decrease of 13.30 percentage points[6] - The total operating costs for Q1 2023 were CNY 71,236,099.36, up from CNY 48,757,775.32 in Q1 2022, indicating a 46.0% increase[19] - The cash paid for purchasing goods and services in Q1 2023 was CNY 33,875,389.57, compared to CNY 16,103,900.51 in Q1 2022, which is a 109.0% increase[22] - The cash paid to employees in Q1 2023 was CNY 49,138,726.29, an increase from CNY 39,188,076.44 in Q1 2022, representing a 25.4% rise[22] Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,721,089,251.57, an increase of 2.19% from the end of the previous year[6] - Total assets as of March 31, 2023, amounted to CNY 1,721,089,251.57, an increase from CNY 1,684,216,383.26 at the end of 2022[15] - Cash and cash equivalents decreased slightly to CNY 1,241,734,956.78 from CNY 1,248,127,080.91[15] - Accounts receivable decreased to CNY 20,378,378.62 from CNY 21,109,272.25, indicating a reduction of approximately 3.46%[15] - Inventory increased to CNY 38,582,312.84 from CNY 34,835,234.85, reflecting an increase of about 10.00%[15] - Total current liabilities rose to CNY 140,512,900.29 from CNY 129,243,639.61, representing an increase of approximately 8.83%[16] - Non-current assets totaled CNY 402,254,702.91, up from CNY 365,006,831.25, marking an increase of about 10.19%[16] - The total liabilities as of Q1 2023 were CNY 167,225,222.37, compared to CNY 155,669,156.83 in the previous year, showing a 7.4% increase[17] - The total equity attributable to shareholders as of Q1 2023 was CNY 1,553,864,029.20, up from CNY 1,528,547,226.43 in Q1 2022, indicating a 1.7% increase[17] - The deferred income tax liabilities decreased to CNY 532,680.04 from CNY 550,724.95, reflecting a 3.3% decrease[17] Cash Flow - Cash flow from operating activities was CNY 11,154,972.16, with no applicable year-on-year comparison[5] - The net cash flow from operating activities for Q1 2023 was $11,154,972.16, a significant improvement compared to a negative cash flow of $4,026,720.88 in Q1 2022, representing a turnaround of over 375%[23] - The total cash outflow from financing activities was $5,159,439.43, compared to $676,260.23 in Q1 2022, indicating an increase of over 663%[23] - The company reported a total cash outflow from operating activities of $113,087,236.15, which is an increase of approximately 34% compared to $84,452,766.78 in Q1 2022[23] - The cash flow from investment activities included cash received from the recovery of investments amounting to $655,000,000.00, down from $1,131,700,000.00 in the previous year, a decrease of about 42%[23] - The company paid $18,593,403.16 for the acquisition of fixed assets and intangible assets, which is an increase from $10,782,947.36 in Q1 2022, reflecting a growth of approximately 72%[23] Shareholder Information - The company has a total of 5,080 common shareholders as of the report date[12] - The top shareholder, Wang Zhiyu, holds 39.29% of the shares, totaling 26,961,547 shares[12] Strategic Developments - The company has not disclosed any significant new strategies or product developments in this report[14]